Roche’s Kadcyla Cuts Risk of Breast Cancer Recurrence After Surgery

Excerpt:

“Roche’s Kadcyla was significantly better than Herceptin at reducing the risk of breast cancer recurrence in certain patients with residual disease after surgery, according to new study findings presented at the San Antonio Breast Cancer Symposium.

“Data from the Phase III KATHERINE study show that Kadcyla (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death by 50% compared to Herceptin (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (eBC) who have residual disease following neoadjuvant therapy.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.